OBJECTIVE: HIV-1 genetic variability may influence antiretroviral therapy (ART) outcomes. The study aim was to determine the impact of polymorphisms in regions known to harbor major nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations (codons 90-108, 135-138, 179-190, 225-348) on virologic responses to first-line NNRTI-based ART. METHODS: Reverse transcriptase sequences from ART-naive individuals who commenced efavirenz (EFV) or nevirapine (NVP) with at least two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) without major drug resistance mutations were analyzed. The impact of polymorphisms on week 4 viral load decrease and time to virologic failure was measured over a median 97 weeks. RESULTS: Among 4528 patients, most were infected with HIV-1 subtype B (67%) and commenced EFV-based ART (84%). Overall, 2598 (57%) had at least one polymorphism, most frequently at codons 90, 98, 101, 103, 106, 135, 138, 179, and 238. Virologic failure rates were increased in patients with two (n = 597) or more than two (n = 72) polymorphisms [adjusted hazard ratio 1.43; 95% confidence interval (CI) 1.07-1.92; P = 0.016]. Polymorphisms associated with virologic failure occurred at codons 90 (mostly V90I), 98 (mostly A98S), and 103 (mostly K103R), with adjusted hazard ratios of 1.78 (1.15-2.73; P = 0.009), 1.55 (1.16-2.08; P = 0.003), and 1.75 (1.00-3.05: P = 0.049), respectively. Polymorphisms at codon 179, especially V179D/E/T, predicted reduced week 4 responses (P = 0.001) but not virologic failure. CONCLUSION: The occurrence of multiple polymorphisms, though uncommon, was associated with a small increase in the risk of NNRTI treatment failure; significant effects were seen with polymorphisms at codon 90, 98, and 103. The mechanisms underlying the slower suppression seen with V179D/E/T deserve further investigation.
OBJECTIVE: HIV-1 genetic variability may influence antiretroviral therapy (ART) outcomes. The study aim was to determine the impact of polymorphisms in regions known to harbor major nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations (codons 90-108, 135-138, 179-190, 225-348) on virologic responses to first-line NNRTI-based ART. METHODS: Reverse transcriptase sequences from ART-naive individuals who commenced efavirenz (EFV) or nevirapine (NVP) with at least two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) without major drug resistance mutations were analyzed. The impact of polymorphisms on week 4 viral load decrease and time to virologic failure was measured over a median 97 weeks. RESULTS: Among 4528 patients, most were infected with HIV-1 subtype B (67%) and commenced EFV-based ART (84%). Overall, 2598 (57%) had at least one polymorphism, most frequently at codons 90, 98, 101, 103, 106, 135, 138, 179, and 238. Virologic failure rates were increased in patients with two (n = 597) or more than two (n = 72) polymorphisms [adjusted hazard ratio 1.43; 95% confidence interval (CI) 1.07-1.92; P = 0.016]. Polymorphisms associated with virologic failure occurred at codons 90 (mostly V90I), 98 (mostly A98S), and 103 (mostly K103R), with adjusted hazard ratios of 1.78 (1.15-2.73; P = 0.009), 1.55 (1.16-2.08; P = 0.003), and 1.75 (1.00-3.05: P = 0.049), respectively. Polymorphisms at codon 179, especially V179D/E/T, predicted reduced week 4 responses (P = 0.001) but not virologic failure. CONCLUSION: The occurrence of multiple polymorphisms, though uncommon, was associated with a small increase in the risk of NNRTI treatment failure; significant effects were seen with polymorphisms at codon 90, 98, and 103. The mechanisms underlying the slower suppression seen with V179D/E/T deserve further investigation.
Authors: Silvia Bertagnolio; Rachel L Beanland; Michael R Jordan; Meg Doherty; Gottfried Hirnschall Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226
Authors: Alessandro Cozzi-Lepri; Marc Noguera-Julian; Francesca Di Giallonardo; Rob Schuurman; Martin Däumer; Sue Aitken; Francesca Ceccherini-Silberstein; Antonella D'Arminio Monforte; Anna Maria Geretti; Clare L Booth; Rolf Kaiser; Claudia Michalik; Klaus Jansen; Bernard Masquelier; Pantxika Bellecave; Roger D Kouyos; Erika Castro; Hansjakob Furrer; Anna Schultze; Huldrych F Günthard; Francoise Brun-Vezinet; Roger Paredes; Karin J Metzner Journal: J Antimicrob Chemother Date: 2014-10-21 Impact factor: 5.790
Authors: Joanna Smoleń-Dzirba; Magdalena Rosińska; Piotr Kruszyński; Jolanta Bratosiewicz-Wąsik; Robert Wojtyczka; Janusz Janiec; Bartosz Szetela; Marek Beniowski; Monika Bociąga-Jasik; Elżbieta Jabłonowska; Tomasz J Wąsik; And The Cascade Collaboration In EuroCoord Journal: Med Sci Monit Date: 2017-02-07
Authors: Roger Paredes; Philip L Tzou; Gert van Zyl; Geoff Barrow; Ricardo Camacho; Sergio Carmona; Philip M Grant; Ravindra K Gupta; Raph L Hamers; P Richard Harrigan; Michael R Jordan; Rami Kantor; David A Katzenstein; Daniel R Kuritzkes; Frank Maldarelli; Dan Otelea; Carole L Wallis; Jonathan M Schapiro; Robert W Shafer Journal: PLoS One Date: 2017-07-28 Impact factor: 3.752
Authors: Gonzalo Yebra; Dan Frampton; Tiziano Gallo Cassarino; Jade Raffle; Jonathan Hubb; R Bridget Ferns; Laura Waters; C Y William Tong; Zisis Kozlakidis; Andrew Hayward; Paul Kellam; Deenan Pillay; Duncan Clark; Eleni Nastouli; Andrew J Leigh Brown Journal: PLoS One Date: 2018-02-01 Impact factor: 3.240